Mobile

An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004696-11

An open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the long-term safety and tolerability of open-label treatment with Sandostatin LAR 30 mg in patients who completed the double-masked study CSMS995 0802

Critère d'inclusion

  • Moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy (PDR)

Liens